Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...

The COVID-19 pandemic engulfed the U.S. five years ago this month, leaving not only lingering mental health effects but also long-term physical symptoms. One of those included a condition known as ...

The primary causes of liver fibrosis include alcohol abuse, chronic hepatitis C virus (HCV) infection, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Despite ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even liver ...

cardiac fibrosis, NASH or NASH, you know, there’s no end to potential applications here. And I think the challenge that we have as a company is to figure out the right path forward, the right non ...

cardiac fibrosis, NASH or NASH, you know, there’s no end to potential applications here. And I think the challenge that we have as a company is to figure out the right path forward, the right ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...

By ITT analysis, with all missing week 96 biopsies treated as failures, 29% of the 50mg EFX group (p=0.031) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, compared to ...